{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T07:35:31Z","timestamp":1774596931186,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is an aggressive B-cell neoplasm with poor prognosis in refractory relapse. Intraocular (vitreoretinal) involvement is extremely rare and represents a diagnostic and therapeutic challenge due to the immune-privileged status of the eye and the risk of central nervous system (CNS) dissemination. Ocular relapse in mantle cell lymphoma has rarely been described, and evidence on the use of CAR-T therapy in this setting is lacking. We report the case of a 61-year-old man with stage IV-B MCL diagnosed in 2018, who experienced multiple relapses and developed intraocular infiltration confirmed by flow cytometric immunophenotyping of vitreous fluid in 2024. After bridging therapy with intravitreal methotrexate, the patient received CD19-directed CAR-T therapy with brexucabtagene autoleucel (Brexucel) as fifth-line treatment, achieving sustained complete metabolic remission with no ocular or systemic relapse after 19 months of follow-up. This case highlights the diagnostic value of flow cytometry in intraocular lymphomas and supports the expanding role of CAR-T therapy in refractory MCL with atypical sanctuary site involvement.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1786040","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:38:07Z","timestamp":1774593487000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Durable remission of intraocular mantle cell lymphoma after CD19 CAR-T therapy"],"prefix":"10.3389","volume":"17","author":[{"given":"\u00c1lvaro","family":"Bienert-Garc\u00eda","sequence":"first","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Arruabarrena","sequence":"additional","affiliation":[{"name":"Servicio Oftalmolog\u00eda, Hospital Universitario Pr\u00edncipe de Asturias, Universidad de Alcal\u00e1 de Henares","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Asencio-Duran","sequence":"additional","affiliation":[{"name":"Servicio Oftalmolog\u00eda, Hospital Universitario La Paz","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta Morado","family":"Arias","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario La Paz","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tycho","family":"Baumann","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia Rodriguez","family":"Izquierdo","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"S\u00e1nchez-Pina","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nieves","family":"L\u00f3pez-Mu\u00f1oz","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gil-Al\u00f3s","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adolfo Jes\u00fas","family":"Saez-Mar\u00edn","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Calbacho","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Jim\u00e9nez-Ubieto","sequence":"additional","affiliation":[{"name":"Servicio Hematolog\u00eda, Hospital Universitario 12 de Octubre, imas12, Universidad Complutense, Spanish National Cancer Research Center (CNIO)","place":["Madrid, Spain"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0210","article-title":"Primary vitreoretinal lymphoma: a report from an International Primary CNS Lymphoma Collaborative Group symposium","volume":"16","author":"Chan","year":"2011","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2008.01843.x","article-title":"Understanding intraocular lymphoma","volume":"92","author":"Coupland","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/mi.2008.27","article-title":"Immune privilege or privileged immunity","volume":"11","author":"Forrester","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24094","article-title":"Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management","volume":"90","author":"Vose","year":"2015","journal-title":"Am J Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347","article-title":"Brexucabtagene autoleucel in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_175448","article-title":"Current approaches to mantle cell lymphoma: diagnosis, prognosis, and therapies","volume":"37","author":"Cohen","year":"2017","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40662-025-00434-4","article-title":"Clinical guidelines for the diagnosis and treatment of primary vitreoretinal lymphoma","volume":"12","author":"Zhang","year":"2025","journal-title":"Eye Vision"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.hemonc.2019.03.002","article-title":"Intraocular involvement of mantle cell lymphoma: literature review","volume":"14","author":"Iqbal","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm340","article-title":"Primary intraocular lymphoma: an international primary CNS lymphoma collaborative group report","volume":"18","author":"Grimm","year":"2007","journal-title":"Ann Oncol"},{"key":"B11","article-title":"Advances in MCL","volume":"5","author":"Wang","year":"2021","journal-title":"HemaSphere"},{"key":"B12","article-title":"Mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Hermine","year":"2022","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/bjh.15283","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"182","author":"McKay","year":"2018","journal-title":"Br J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the GELTAMO group","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"key":"B15","first-page":"1","article-title":"Current concepts in diagnosing and managing primary intraocular lymphoma","volume":"14","author":"Chan","year":"2019","journal-title":"Expert Rev Ophthalmol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030598","article-title":"Diagnosing vitreoretinal lymphomas: a systematic analysis","volume":"198","author":"Sehgal","year":"2022","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2021.1878233","article-title":"Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma","volume":"29","author":"Carbonell","year":"2021","journal-title":"Ocul Immunol Inflamm"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.06-0031","article-title":"Interleukin-10 measurement in aqueous humor for screening of primary intraocular lymphoma","volume":"144","author":"Cassoux","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"B19","article-title":"Limitations of PET\/CT in detecting primary intraocular lymphoma: a clinicopathologic correlation","volume":"2","author":"Moslehi","year":"2016","journal-title":"Ocul Oncol Pathol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e70208","DOI":"10.1002\/hem3.70208","article-title":"Preliminary evidence of CAR T-cell therapy activity in vitreoretinal lymphomas: An LOC network study","volume":"9","author":"Pivert","year":"2025","journal-title":"HemaSphere"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19037","article-title":"Clinical efficacy and safety of chimeric antigen receptor T-cell therapy for mantle cell lymphoma with secondary central nervous system involvement","volume":"203","author":"Ryan","year":"2023","journal-title":"Br J Haematol"},{"key":"B22","article-title":"Successful control of vitreoretinal lymphoma using intravitreal CAR T cells in a mouse model","volume":"137","author":"Suneja","year":"2021","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14025","article-title":"How we diagnose and treat vitreoretinal lymphoma","volume":"173","author":"Fend","year":"2016","journal-title":"Br J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70208","article-title":"Anti-CD19 CAR T-cell therapy for vitreoretinal lymphoma: experience from the UK LOC Network","volume":"203","author":"Bagchi","year":"2023","journal-title":"Br J Haematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2025.2458214","article-title":"CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges","volume":"66","author":"Xiong","year":"2025","journal-title":"Leuk Lymphoma"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786040\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T06:38:08Z","timestamp":1774593488000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1786040\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,27]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1786040"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1786040","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,27]]},"article-number":"1786040"}}